FindTrial
Sign In

Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00800852
Enrollment
Unknown
Registered
2008-12-02
Start date
Unknown
Completion date
Unknown
Last updated
2008-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Prader-Willi Syndrome

Keywords

adiponectin, adiponectin receptor, Prader-Willi syndrome

Brief summary

The inflammatory process is involved in the pathogenesis of obesity. Prader-Willi syndrome (PWS) is a genetic model of syndromic obesity. Adiponectin is an adipokine with potent anti-inflammatory properties, and its effect is mediated through adiponectin receptors 1 (adipoR1) and 2 (adipoR2). Objective of this study is to compare the expression of adipoR1, adipoR2, and adiponectin in peripheral blood mononuclear cells (PBMCs) in PWS children and obese control and to correlate receptor expression with insulin sensitivity and obesity-related parameters.

Interventions

None listed

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* children with Prader-willi syndrome * children with simple obesity

Exclusion criteria

* subjects with diabetes mellitus (fasting plasma glucose \> 126 mg/dL with a 2-h oral glucose tolerance test value of \>200 mg/dl)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026